Processing

Please wait...

Settings

Settings

Goto Application

1. WO1997025959 - COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF ATHEROSCLEROSIS AND REPERFUSION INJURY WITH MAGNESIUM SALTS

Publication Number WO/1997/025959
Publication Date 24.07.1997
International Application No. PCT/US1997/000821
International Filing Date 17.01.1997
Chapter 2 Demand Filed 18.08.1997
IPC
A61K 31/191 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
19Carboxylic acids, e.g. valproic acid
191Acyclic acids having two or more hydroxy groups, e.g. gluconic acid
A61K 33/06 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
33Medicinal preparations containing inorganic active ingredients
06Aluminium, calcium or magnesium; Compounds thereof
A61K 38/06 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
06Tripeptides
A61K 47/26 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/12 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
08containing oxygen
12Carboxylic acids; Salts or anhydrides thereof
CPC
A61K 31/191
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
19Carboxylic acids, e.g. valproic acid
191having two or more hydroxy groups, e.g. gluconic acid
A61K 33/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
33Medicinal preparations containing inorganic active ingredients
06Aluminium, calcium or magnesium; Compounds thereof ; , e.g. clay
A61K 38/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
06Tripeptides
A61K 47/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
08containing oxygen, ; e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
12Carboxylic acids; Salts or anhydrides thereof
A61K 47/26
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 9/0019
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
0012Galenical forms characterised by the site of application
0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Applicants
  • FLEMING & COMPANY, PHARMACEUTICALS [US]/[US] (AllExceptUS)
  • FLEMING, Thomas, E. [US]/[US] (UsOnly)
  • MANSMANN, Herbert, C., Jr. [US]/[US] (UsOnly)
Inventors
  • FLEMING, Thomas, E.
  • MANSMANN, Herbert, C., Jr.
Agents
  • STIEFEL, Maurice, B.
Priority Data
08/588,56418.01.1996US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF ATHEROSCLEROSIS AND REPERFUSION INJURY WITH MAGNESIUM SALTS
(FR) COMPOSITIONS ET PROCEDES S'APPLIQUANT A LA PREVENTION ET AU TRAITEMENT DE L'ATHEROSCLEROSE ET DES LESIONS CONSECUTIVES A DES PERFUSIONS AU MOYEN DE SELS DE MAGNESIUM
Abstract
(EN)
The present invention provides compositions and methods for the prevention or treatment of atherosclerosis and reperfusion injury. The method comprises administering to a patient having atherosclerosis an aqueous solution containing magnesium gluconate in an amount sufficient to inhibit oxygen free radical production and lipid peroxidation. In another embodiment the invention provides for the prevention of restenosis in patients undergoing bypass surgery or angioplasty. In a different embodiment, the present invention provides a method for prevention or treatment of ischemic reperfusion injury comprising the step of administering to a patient at risk of reperfusion injury a therapeutically effective amount of magnesium gluconate to inhibit oxygen free radical production. The aqueous solution of the invention comprises magnesium gluconate in an amount sufficient to inhibit oxygen free radical production in cardiac and endothelial tissues.
(FR)
La présente invention se rapporte à des compositions et à des procédés s'appliquant à la prévention ou au traitement de l'athérosclérose et des lésions consécutives à des perfusions. Ce procédé consiste à administrer à un patient souffrant d'athérosclérose une solution aqueuse contenant un gluconate de magnésium dans une quantité suffisante pour inhiber la formation de radicaux libres provoquée par l'oxygène et la peroxydation lipidique. Selon une autre réalisation, l'invention se rapporte à la prévention de la resténose chez des patients subissant une intervention chirurgicale de pontage ou d'angioplastie. Selon une réalisation différente, la présente invention se rapporte à un procédé de prévention ou de traitement de lésions ischémiques consécutives à des perfusions, procédé consistant à administrer à un patient sujet aux lésions consécutives à des perfusions une quantité thérapeutiquement efficace de gluconate de magnésium afin d'inhiber la formation de radicaux libres provoquée par l'oxygène. La solution aqueuse de l'invention comprend du gluconate de magnésium dans une quantité suffisante permettant d'inhiber la formation de radicaux libres provoquée par l'oxygène dans les tissus cardiaques et endothéliaux.
Latest bibliographic data on file with the International Bureau